43024 Federal Register / Vol. 82, No. 176 / Wednesday, September 13, 2017 / Notices 

a final rule, advice on the scientific 

validity and quality of dose estimation 

and reconstruction efforts being 

performed for purposes of the 

compensation program, and advice on 

petitions to add classes of workers to the 

Special Exposure Cohort (SEC). In 

December 2000, the President delegated 

responsibility for funding, staffing, and 

operating the Advisory Board to HHS, 

which subsequently delegated this 

authority to the CDC. NIOSH 

implements this responsibility for CDC. 

The charter was issued on August 3, 

2001, renewed at appropriate intervals, 

rechartered on March 22, 2016 pursuant 

to Executive Order 13708, and will 

expire on September 30, 2017. 

Purpose: This Advisory Board is 

charged with (a) providing advice to the 

Secretary, HHS, on the development of 

guidelines under Executive Order 

13179; (b) providing advice to the 

Secretary, HHS, on the scientific 

validity and quality of dose 

reconstruction efforts performed for this 

program; and (c) upon request by the 

Secretary, HHS, advising the Secretary 

on whether there is a class of employees 

at any Department of Energy facility 

who were exposed to radiation but for 

whom it is not feasible to estimate their 

radiation dose, and on whether there is 

reasonable likelihood that such 

radiation doses may have endangered 

the health of members of this class. 

Matters To Be Considered: The agenda 

will include discussions on: Final Vote 

Counts from the August ABRWH 

Meeting for Feeds Material Production 

Center SEC petition (Fernald, OH), 

Idaho National Laboratory SEC petition 

(Scoville, ID), and Grand Junction 

Facilities SEC petition (Grand Junction, 

CO); Savannah River Site SEC Petition 

(Aiken, SC); Work Group and 

Subcommittee Reports; Update on the 

Status of SEC Petitions; Plans for the 

December 2017 Advisory Board 

Meeting; and Advisory Board 

Correspondence. Agenda items are 

subject to change as priorities dictate. 

The Director, Management Analysis 

and Services Office, has been delegated 

the authority to sign Federal Register 

notices pertaining to announcements of 

meetings and other committee 

management activities, for both the 

Centers for Disease Control and 

Prevention and the Agency for Toxic 

Substances and Disease Registry. 

Claudette Grant, 

Acting Director, Management Analysis and 

Services Office, Centers for Disease Control 

and Prevention. 

[FR Doc. 2017–19443 Filed 9–12–17; 8:45 am] 

BILLING CODE 4163–19–P 

DEPARTMENT OF HEALTH AND 

HUMAN SERVICES 

Centers for Disease Control and 

Prevention 

National Center for Health Statistics 

(NCHS), ICD–10 Coordination and 

Maintenance (C&M) Committee 

Meeting 

AGENCY: Centers for Disease Control and 

Prevention (CDC), Department of Health 

and Human Services (HHS). 

ACTION: Notice of meeting. 

SUMMARY: The Centers for Disease 

Control and Prevention, National Center 

for Health Statistics (NCHS), 

Classifications and Public Health Data 

Standards Staff, announces the 

following meeting of the ICD–10 

Coordination and Maintenance (C&M) 

Committee meeting. This meeting is 

open to the public, limited only by the 

space available. The meeting room 

accommodates approximately 240 

people. We will be broadcasting the 

meeting live via Webcast at http://

www.cms.gov/live/. 

DATES: The meeting will be held on 

September 12, 2017, 8:00 a.m. to 5:00 

p.m. EDT and September 13, 2017, 8:00 

a.m. to 5:00 p.m. EDT. 

ADDRESSES: Centers for Medicare and 

Medicaid Services (CMS) Auditorium, 

7500 Security Boulevard, Baltimore, 

Maryland 21244. 

FOR FURTHER INFORMATION CONTACT: 

Traci Ramirez, CCA, Program Specialist, 

CDC, National Center for Health 

Statistics (NCHS), Classifications and 

Public Health Data Standards Staff 

(CPHDSS), 3311 Toledo Rd., Hyattsville, 

Maryland 20715, telephone (301) 458– 

4454, tfr4@cdc.gov. 

SUPPLEMENTARY INFORMATION: 

Purpose: The ICD–10 Coordination 

and Maintenance (C&M) Committee is a 

public forum for the presentation of 

proposed modifications to the 

International Classification of Diseases, 

Tenth Revision, Clinical Modification 

and ICD–10 Procedure Coding System. 

Matters To Be Considered: The agenda 

will include discussions on. 

ICD–10–PCS Topics 

Irreversible Electroporation (IRE) 

Shunt Ligation/Occlusion 

Spinal Fusion with Interbody Fusion 

Device 

Bypass Descending Thoracic Aorta to 

Abdominal Artery 

ICD–10–CM Diagnosis Topics 

Anemia due to Myelosuppressive 

Antineoplastic Chemotherapy 

Cyclic Vomiting 

Ecstasy Classification 

Elevated Lipoprotein(a) 

Factitious Disorder 

Incontinence-Associated Dermatitis 

(IAD) 

Intracranial Hypotension 

Muscular Dystrophy 

Neonatal Metabolic Disturbances 

Other Doubling of Uterus 

Primary Sclerosing Cholangitis 

Tarlov Perineural Cysts 

Williams Syndrome 

Zika related newborn conditions 

ICD–10–CM Addendum 

Agenda items are subject to change as 

priorities dictate. 

Security Considerations: Due to 

increased security requirements CMS 

has instituted stringent procedures for 

entrance into the building by nongovernment employees. Attendees will 

need to present valid government-issued 

picture identification, and sign-in at the 

security desk upon entering the 

building. Attendees who wish to attend 

the September 12–13, 2017, ICD–10–CM 

C&M meeting must submit their name 

and organization by September 8, 2017, 

for inclusion on the visitor list. This 

visitor list will be maintained at the 

front desk of the CMS building and used 

by the guards to admit visitors to the 

meeting. 

Participants who attended previous 

Coordination and Maintenance meetings 

will no longer be automatically added to 

the visitor list. You must request 

inclusion of your name prior to each 

meeting you wish attend. 

Please register to attend the meeting 

on-line at: http://www.cms.hhs.gov/ 

apps/events/. 

Please contact Mady Hue (410–786– 

4510 or Marilu.hue@cms.hhs.gov), for 

questions about the registration process. 

Note: CMS and NCHS no longer provide 

paper copies of handouts for the meeting. 

Electronic copies of all meeting materials 

will be posted on the CMS and NCHS Web 

sites prior to the meeting at http://

www.cms.hhs.gov/ICD9ProviderDiagnostic

Codes/03_meetings.asp#TopOfPage and 

https://www.cdc.gov/nchs/icd/icd10cm_

maintenance.htm. 

The Director, Management Analysis 

and Services Office, has been delegated 

the authority to sign Federal Register 

notices pertaining to announcements of 

meetings and other committee 

management activities, for both the 

Centers for Disease Control and 


sradovich on DSK3GMQ082PROD with NOTICES
Federal Register / Vol. 82, No. 176 / Wednesday, September 13, 2017 / Notices 43025 

Prevention, and the Agency for Toxic 

Substances and Disease Registry. 

Claudette Grant, 

Acting Director, Management Analysis and 

Services Office, Centers for Disease Control 

and Prevention. 

[FR Doc. 2017–19444 Filed 9–12–17; 8:45 am] 

BILLING CODE 4160–18–P 

DEPARTMENT OF HEALTH AND 

HUMAN SERVICES 

Administration for Children and 

Families 

Proposed Information Collection 

Activity; Comment Request 

Proposed Projects: Grant Reviewer 

Recruitment and Recordkeeping. 

Title: Case Plan Requirement, Title 

IV–E of the Social Security Act. 

OMB No.: 0970–0428. 

Respondents: State and Tribe title IV– 

B and title IV–E agencies. 

Description: Under section 471(a)(16) 

of title IV–E of the Social Security Act 

(the Act), to be eligible for payments, 

states and tribes must have an approved 

title IV–E plan that provides for the 

development of a case plan for each 

child for whom the State or Tribe 

receives foster care maintenance 

payments and that provides a case 

review system that meets the 

requirements in section 475(5) and 

475(6) of the Act. 

The case review system assures that 

each child has a case plan designed to 

achieve placement in a safe setting that 

is the least restrictive (most family-like) 

setting available and in close proximity 

to the child’s parental home, consistent 

with the best interest and special needs 

of the child. Through these 

requirements, States and Tribes also 

comply, in part, with title IV–B section 

422(b) of the Act, which assures certain 

protections for children in foster care. 

The case plan is a written document 

that provides a narrative description of 

the child-specific program of care. 

Federal regulations at 45 CFR 1356.21(g) 

and section 475(1) of the Act delineate 

the specific information that should be 

addressed in the case plan. The 

Administration for Children and 

Families (ACF) does not specify a 

recordkeeping format for the case plan 

nor does ACF require submission of the 

document to the Federal government. 

Case plan information is recorded in a 

format developed and maintained by the 

State or Tribal child welfare agency. 

ANNUAL BURDEN ESTIMATES

Instrument Number of 

respondents 

Number of 

responses per 

respondent 

Average 

burden hours 

per response 

Total burden 

hours 

Case Plan ........................................................................................................ 544,098 1 4.80 2,626,436 

Estimated Total Annual Burden 

Hours: 2,626,436. 

In compliance with the requirements 

of the Paperwork Reduction Act of 1995 

(Pub. L. 104–13, 44 U.S.C. Chap 35), the 

Administration for Children and 

Families is soliciting public comment 

on the specific aspects of the 

information collection described above. 

Copies of the proposed collection of 

information may be obtained and 

comments may be forwarded by writing 

to the Administration for Children and 

Families, Office of Planning, Research 

and Evaluation, 330 C Street SW., 

Washington, DC 20201. Attn: ACF 

Reports Clearance Officer. Email 

address: infocollection@acf.hhs.gov. All 

requests should be identified by the title 

of the information collection. 

The Department specifically requests 

comments on: (a) Whether the proposed 

collection of information is necessary 

for the proper performance of the 

functions of the agency, including 

whether the information shall have 

practical utility; (b) the accuracy of the 

agency’s estimate of the burden of the 

proposed collection of information; (c) 

the quality, utility, and clarity of the 

information to be collected; and (d) 

ways to minimize the burden of the 

collection of information on 

respondents, including through the use 

of automated collection techniques or 

other forms of information technology. 

Consideration will be given to 

comments and suggestions submitted 

within 60 days of this publication. 

Robert Sargis, 

Reports Clearance Officer. 

[FR Doc. 2017–19367 Filed 9–12–17; 8:45 am] 

BILLING CODE 4184–25–P 

DEPARTMENT OF HEALTH AND 

HUMAN SERVICES 

Food and Drug Administration 

[Docket No. FDA–2017–D–5297] 

Microdose Radiopharmaceutical 

Diagnostic Drugs: Nonclinical Study 

Recommendations; Draft Guidance for 

Industry; Availability 

AGENCY: Food and Drug Administration, 

HHS. 

ACTION: Notice of availability. 

SUMMARY: The Food and Drug 

Administration (FDA or Agency) is 

announcing the availability of a draft 

guidance for industry entitled 

‘‘Microdose Radiopharmaceutical 

Diagnostic Drugs: Nonclinical Study 

Recommendations.’’ This draft guidance 

is intended to assist developers of 

microdose radiopharmaceutical 

diagnostic drugs on the nonclinical 

studies recommended to support human 

clinical trials and marketing 

authorization. The draft guidance 

discusses how to refine nonclinical 

study recommendations for this class of 

drug given its unique characteristics. 

This draft guidance is intended to 

provide recommendations for a pathway 

to full drug development (marketing 

authorization) for microdose 

radiopharmaceutical diagnostic drugs. 

DATES: Submit either electronic or 

written comments on the draft guidance 

by November 13, 2017 to ensure that the 

Agency considers your comment on this 

draft guidance before it begins work on 

the final version of the guidance. 

ADDRESSES: You may submit comments 

on any guidance at any time as follows: 

Electronic Submissions 

Submit electronic comments in the 

following way: 

• Federal eRulemaking Portal: 

https://www.regulations.gov. Follow the 

instructions for submitting comments. 

Comments submitted electronically, 

including attachments, to https://

www.regulations.gov will be posted to 

the docket unchanged. Because your 

comment will be made public, you are 

solely responsible for ensuring that your 

comment does not include any 

confidential information that you or a 

third party may not wish to be posted, 

such as medical information, your or 

anyone else’s Social Security number, or 

confidential business information, such 

as a manufacturing process. Please note 

that if you include your name, contact 

information, or other information that 


sradovich on DSK3GMQ082PROD with NOTICES